Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05665062 · ClinicalTrials.gov registry record · Phase 1
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
A Phase 1 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, sponsored by Synthekine.
- Active
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT05665062 is a Phase 1 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma that is active but no longer recruiting, run by Synthekine. The registered enrollment target is 36 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (83% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05665062, a Phase 1 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, is active but no longer recruiting, sponsored by Synthekine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG SYNCAR-001
- DRUG STK-009
Study Locations (4)
New York
- Roswell Park - Buffalo
- Memorial Sloan Kettering Cancer Center - New York
California
- City of Hope - Duarte
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-04-23 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05665062
The ClinicalTrials.gov registry entry for NCT05665062 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (83% lower). The listed sponsor is Synthekine, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT05665062 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New York, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT05665062 about?
NCT05665062 is a clinical study titled "Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies". This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
What is the current status of trial NCT05665062?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-04-23. Estimated completion is 2026-11.
What conditions does trial NCT05665062 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, NHL.
What interventions are being tested in trial NCT05665062?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), SYNCAR-001 (DRUG), STK-009 (DRUG).
Who is sponsoring clinical trial NCT05665062?
This trial is sponsored by Synthekine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05665062 being conducted?
This trial has 4 study locations across California, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.